Hydrocortisonum-Sf (Hydrocortisone)

Hydrocortisonum‑Sf is indicated for several clinical situations where glucocorticoid activity is required.

• Adrenal insufficiency (primary or secondary) requiring cortisol replacement
• Management of acute inflammatory disorders such as severe asthma exacerbations
• Treatment of allergic reactions that are not controlled by antihistamines
• Replacement therapy in patients with congenital adrenal hyperplasia
• Short‑term control of autoimmune conditions when rapid anti‑inflammatory effect is needed

• Hydrocortisonum‑Sf delivers hydrocortisone, a synthetic analogue of endogenous cortisol, which binds to intracellular glucocorticoid receptors. The receptor‑ligand complex translocates to the nucleus and modulates gene transcription, leading to decreased production of pro‑inflammatory cytokines, inhibition of phospholipase A2, and suppression of the arachidonic acid pathway. These actions collectively reduce inflammation, limit immune cell activation, and restore metabolic functions that depend on cortisol.

Like other systemic corticosteroids, hydrocortisone may cause a range of adverse reactions, which vary in frequency and severity.

Common

• Increased appetite or weight gain
• Fluid retention leading to mild edema
• Elevated blood glucose levels, especially in diabetic patients
• Mood changes such as irritability or insomnia
• Gastrointestinal discomfort, including nausea

Serious

• Severe hyperglycemia or new‑onset diabetes
• Hypertension or worsening of existing high blood pressure
• Osteoporosis or increased risk of fractures
• Suppression of the hypothalamic‑pituitary‑adrenal axis
• Opportunistic infections due to immune suppression

Before initiating Hydrocortisonum‑Sf, clinicians should evaluate several precautionary factors to minimize risk.

• Assess for active infections; corticosteroids can exacerbate bacterial, viral, or fungal diseases.
• Review patient history for uncontrolled diabetes, hypertension, or osteoporosis.
• Use the lowest effective dose for the shortest duration needed.
• Monitor electrolyte balance, especially sodium and potassium, during therapy.
• Evaluate for signs of adrenal suppression when discontinuing after prolonged use.
• Consider alternative therapies in pregnant or nursing women, as safety data are limited.
• Perform regular bone density assessments for long‑term users.

Hydrocortisonum‑Sf can alter the pharmacokinetics or pharmacodynamics of several medicines; awareness of these interactions helps prevent complications.

Avoid

• Strong CYP3A4 inducers such as rifampin, phenytoin, or carbamazepine, which may reduce hydrocortisone exposure.
• Systemic antifungal agents (e.g., ketoconazole, itraconazole) that can increase corticosteroid levels.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) due to additive risk of gastrointestinal bleeding.
• Anticoagulants (e.g., warfarin) because corticosteroids may affect clotting parameters.
• Diabetic medications, as hydrocortisone can raise blood glucose.
• Vaccines, particularly live attenuated vaccines, because of immunosuppression.